Armistice Capital LLC Has $141.03 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Armistice Capital LLC boosted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 47.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,272,000 shares of the specialty pharmaceutical company's stock after purchasing an additional 1,700,000 shares during the period. Supernus Pharmaceuticals comprises about 1.8% of Armistice Capital LLC's holdings, making the stock its 3rd largest holding. Armistice Capital LLC owned about 9.57% of Supernus Pharmaceuticals worth $141,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of SUPN. Cubist Systematic Strategies LLC boosted its holdings in shares of Supernus Pharmaceuticals by 98.3% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 79,632 shares of the specialty pharmaceutical company's stock valued at $2,130,000 after acquiring an additional 39,479 shares in the last quarter. Marshall Wace LLP bought a new position in Supernus Pharmaceuticals in the second quarter valued at about $1,967,000. Bank of Montreal Can boosted its stake in shares of Supernus Pharmaceuticals by 1,508.0% during the second quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company's stock valued at $3,287,000 after purchasing an additional 109,088 shares in the last quarter. Public Sector Pension Investment Board increased its stake in shares of Supernus Pharmaceuticals by 8.0% in the second quarter. Public Sector Pension Investment Board now owns 120,949 shares of the specialty pharmaceutical company's stock valued at $3,235,000 after buying an additional 8,967 shares during the period. Finally, ProShare Advisors LLC increased its stake in shares of Supernus Pharmaceuticals by 59.8% in the second quarter. ProShare Advisors LLC now owns 22,152 shares of the specialty pharmaceutical company's stock valued at $593,000 after buying an additional 8,293 shares during the period.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock traded up $0.83 during midday trading on Thursday, reaching $30.77. The company had a trading volume of 306,090 shares, compared to its average volume of 467,750. The stock has a fifty day moving average price of $32.23 and a 200 day moving average price of $30.44. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $21.99 and a fifty-two week high of $35.44. The firm has a market cap of $1.69 billion, a PE ratio of -103.79 and a beta of 0.88.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The firm had revenue of $168.30 million during the quarter, compared to analyst estimates of $148.83 million. During the same quarter last year, the firm posted ($0.02) EPS. The firm's revenue for the quarter was up 24.1% on a year-over-year basis. As a group, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on SUPN shares. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, August 7th. Piper Sandler downgraded Supernus Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price objective for the company from $41.00 to $36.00 in a report on Wednesday, September 11th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.